	2019 Mar 31	2020 Mar 31	R 2021 Mar 31	2022 Mar 31	R 2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M PR	12M PR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Total Revenue	62.50	75.23	52.27	74.71	99.17	99.33	89.85	106.91
Cost of Operating Revenue	19.24	24.71	20.08	25.41	30.22	28.85	20.91	25.06
Gross Profit	43.26	50.52	32.20	49.30	68.95	70.48	68.94	81.85
Gross Margin	69.2	67.2	61.6	66.0	69.5	71.0	76.7	76.6
Total Operating Expenses	61.12	74.81	51.58	70.10	93.89	97.89	80.50	97.62
Operating Profit	1.38	0.42	0.69	4.61	5.28	1.44	9.35	9.29
Operating Margin	2.2	0.6	1.3	6.2	5.3	1.5	10.4	8.7
Financing Income/(Expense) - Net	-0.57	-0.92	-0.30	-0.05	0.69	1.00	1.37	-0.85
Profit before Taxes	0.88	-0.45	0.45	4.75	6.43	2.86	9.90	10.81
Income Taxes	0.39	0.11	0.06	1.28	1.60	0.87	2.74	1.82
Profit after Tax	0.50	-0.56	0.39	3.47	4.83	1.98	7.14	8.99
PAT Margin	0.8	-0.7	0.7	4.6	4.9	2.0	7.9	8.4
EPS - Basic - ex Extraordinary Items	110.20	-0.53	0.37	3.30	4.60	1.88	6.79	8.51
EPS - Diluted - ex Extraordinary Items	110.20	-0.53	0.37	3.30	4.60	1.57	5.78	8.51
EBIT	1.38	0.42	0.69	4.61	5.28	1.44	9.35	9.29
EBITDA	2.97	2.65	3.14	6.90	7.88	4.58	13.50	15.42
EBITDA Margin	4.7	3.5	6.0	9.2	7.9	4.6	15.0	14.4

Balance Sheet

Abridged

Understanding Balance Sheet

Vaidya Sane Ayurved Laboratories Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2019 Mar 31	2020 Mar 31	2021 Mar 31	R 2022 Mar 31	R 2023 Mar 31	R 2024 Mar 31	2025 Mar 31	2026 Mar 31

Source:	PR	PR	PR	AR	AR	AR	AR	PRESS
Total Current Assets	10.04	8.50	7.19	25.48	27.78	31.35	30.28	44.31
Long-Term Investments	0.02	0.02	0.01	4.88	1.53	2.00	6.36	17.26
Property Plant & Equipment - Net	16.19	18.18	17.08	17.19	20.11	23.02	21.45	24.08
Total Non-Current Assets	18.84	20.61	18.62	24.53	27.10	38.36	46.42	60.20
Total Assets	28.88	29.11	25.81	50.01	54.88	69.71	76.71	104.51
Total Current Liabilities	19.03	18.75	13.92	12.51	12.88	11.62	11.22	11.11
Long Term Debt	-	-	-	-	-	-	-	2.59
Total Non-Current Liabilities	1.07	2.14	2.12	1.61	1.55	2.49	2.95	5.96
Total Liabilities	20.10	20.89	16.04	14.12	14.43	14.11	14.17	17.07
Total Shareholders' Equity	8.78	8.22	9.77	35.88	40.45	55.60	62.54	87.44
Minority Interest	-	-	-	-	0.00	0.00	0.00	0.00
Total Equity	8.78	8.22	9.77	35.88	40.45	55.60	62.54	87.44
Total Liabilities & Equity	28.88	29.11	25.81	50.01	54.88	69.71	76.71	104.51

Cash Flow

Abridged

Understanding Cash Flow Statement

Vaidya Sane Ayurved Laboratories Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	R 2023 Mar 31	R 2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M PR	12M PR	12M PR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Operating CF bef Changes in Working Cap	2.05	1.58	3.44	5.84	5.92	4.69	12.46	14.84
Working Capital - Increase/(Decrease)	-0.96	5.27	1.77	-19.02	-5.17	-5.32	-0.46	-7.62
Net CF from Operating Activities	1.09	6.85	5.21	-13.18	0.75	-0.63	11.99	7.22
Capital Expenditures - Net	8.97	3.85	0.68	2.99	6.98	11.15	8.45	7.88
Net CF from Investing Activities	-10.13	-4.00	-0.41	-7.86	-0.35	-13.87	-11.57	-26.01
Dividends Paid - Cash - Total	-	-	-	-	0.26	-	-	-
Stock - Issuance/(Retirement) - Net	-	-	-	3.54	-	13.43	0.00	-0.01
Debt - LT & ST - Issuance/(Retirement) - Total	8.27	-2.70	-4.95	0.05	-0.93	1.68	-0.22	1.11
Net Cash Flow from Financing Activities	8.27	-2.70	-4.95	22.69	-1.19	15.11	-0.43	16.86
Free Cash Flow to Equity	0.39	0.30	-0.42	-16.12	-7.16	-10.10	3.33	0.45
Free Operating CF net dividend	-7.88	3.00	4.53	-16.35	-6.49	-11.78	3.55	-0.66
Free Operating CF	-7.88	3.00	4.53	-16.35	-6.23	-11.78	3.55	-0.66

Business Segment Analysis

FY End:

Mar 24

Vaidya Sane Ayurved Laboratories Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Common/Unallocable (72.6%)₹ 3.80 CrHospitality (27.4%)₹ 1.44 CrSale of product activity (0.0%)₹ 0.00 Cr

Revenue / Sales

Sale of product activity (65.6%)₹ 65.20 CrHospitality (21.9%)₹ 21.74 CrCommon/Unallocable (12.5%)₹ 12.39 Cr

Assets

Common/Unallocable (78.8%)₹ 55.84 CrHospitality (21.2%)₹ 15.05 Cr

Operating Income

Common/Unallocable (46.6%)₹ -43.48 CrSale of product activity (45.0%)₹ 41.94 CrHospitality (8.4%)₹ 7.79 Cr

Regional Segment Analysis

Vaidya Sane Ayurved Laboratories Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

We don't have enough data to show regional segment analysis for Vaidya Sane Ayurved Laboratories Ltd.

Historical Segment Analysis

Track how Vaidya Sane Ayurved Laboratories Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31

Common/Unallocable	1	3	8	4
Hospitality	0	0	0	1
Sale of product activity	0	0	0	0

Frequently Asked Questions

What is the revenue of Vaidya Sane Ayurved Laboratories Ltd.?

The latest trailing twelve month revenue of Vaidya Sane Ayurved Laboratories Ltd. is ₹ 106.91 Cr, reflecting a 1-year growth of 18.99% and a 3-year CAGR of 2.59%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Vaidya Sane Ayurved Laboratories Ltd.?

The latest trailing twelve month net profit (PAT) of Vaidya Sane Ayurved Laboratories Ltd. is ₹ 8.99 Cr, with a 3-year earnings CAGR of 19.90%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Vaidya Sane Ayurved Laboratories Ltd.?

The trailing twelve month EBITDA of Vaidya Sane Ayurved Laboratories Ltd. is approximately ₹ 9.29 Cr (based on an operating margin of 8.69%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Vaidya Sane Ayurved Laboratories Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Vaidya Sane Ayurved Laboratories Ltd. is 8.51. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Vaidya Sane Ayurved Laboratories Ltd.?

The debt-to-equity ratio of Vaidya Sane Ayurved Laboratories Ltd. stands at 0.03. The interest coverage ratio is 10.93x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Vaidya Sane Ayurved Laboratories Ltd.?

The estimated book value per share of Vaidya Sane Ayurved Laboratories Ltd. is 83.17 (derived from a P/B ratio of 2.27 and market price of ₹ 188.85), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Vaidya Sane Ayurved Laboratories Ltd.?

The trailing twelve month operating cash flow of Vaidya Sane Ayurved Laboratories Ltd. is ₹ 7.22 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Vaidya Sane Ayurved Laboratories Ltd. report consolidated or standalone financials?

Vaidya Sane Ayurved Laboratories Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.